Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Relay Therapeutics stock

Own Relay Therapeutics stock in just a few minutes.

Relay Therapeutics, Inc is a biotechnology business based in the US. Relay Therapeutics shares (RLAY) are listed on the NASDAQ and all prices are listed in US Dollars. Relay Therapeutics employs 159 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Relay Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RLAY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Relay Therapeutics share price

Use our graph to track the performance of RLAY stocks over time.

Relay Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$30.72 - $64.37
50-day moving average $35.94
200-day moving average $43.27
Wall St. target price$54.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.99

Buy Relay Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Relay Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Relay Therapeutics financials

Revenue TTM $82.7 million
Gross profit TTM $82.7 million
Return on assets TTM -5.85%
Return on equity TTM -9.35%
Profit margin -63.41%
Book value N/A
Market capitalisation $3.1 billion

TTM: trailing 12 months

Shorting Relay Therapeutics shares

There are currently 8.2 million Relay Therapeutics shares held short by investors – that's known as Relay Therapeutics's "short interest". This figure is 23.4% up from 6.6 million last month.

There are a few different ways that this level of interest in shorting Relay Therapeutics shares can be evaluated.

Relay Therapeutics's "short interest ratio" (SIR)

Relay Therapeutics's "short interest ratio" (SIR) is the quantity of Relay Therapeutics shares currently shorted divided by the average quantity of Relay Therapeutics shares traded daily (recently around 904405.3038674). Relay Therapeutics's SIR currently stands at 9.05. In other words for every 100,000 Relay Therapeutics shares traded daily on the market, roughly 9050 shares are currently held short.

However Relay Therapeutics's short interest can also be evaluated against the total number of Relay Therapeutics shares, or, against the total number of tradable Relay Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Relay Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Relay Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1407% of the tradable shares (for every 100,000 tradable Relay Therapeutics shares, roughly 141 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Relay Therapeutics.

Find out more about how you can short Relay Therapeutics stock.

Relay Therapeutics share dividends

We're not expecting Relay Therapeutics to pay a dividend over the next 12 months.

Relay Therapeutics overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site